Anzeige
Mehr »
Dienstag, 14.07.2026 - Börsentäglich über 12.000 News
Time to Buy! Diese drei Kräfte treiben die Tiefsee-Exploration massiv an
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A407RQ | ISIN: US81751A1088 | Ticker-Symbol: 2BO
Tradegate
14.07.26 | 07:45
1,800 Euro
-1,64 % -0,030
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SERINA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SERINA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,8101,91022:00

Aktuelle News zur SERINA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoSerina Therapeutics, Inc.: Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease62Data Safety Monitoring Committee completed initial review of sentinel dosing observations and recommended continued dosing in Cohort 1 - Dosing of additional patients in Cohort 1 is underway at sites...
► Artikel lesen
24.06.Serina Therapeutics, Inc. - 8-K, Current Report1
14.05.Serina Therapeutics GAAP EPS of -$0.58 misses by $0.143
14.05.Serina Therapeutics, Inc.: Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates240Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson's Disease; TFL data from the SAD study arm targeted for first half of 2027 - - Closed $21.2 million private placement...
► Artikel lesen
21.04.Serina Therapeutics, Inc. - 8-K, Current Report2
07.04.Serina Therapeutics, Inc.: Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit2
02.04.Serina Therapeutics wins NYSE approval; 2027 listing compliance deadline set9
SERINA THERAPEUTICS Aktie jetzt für 0€ handeln
02.04.Serina Therapeutics, Inc.: Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan206HUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform...
► Artikel lesen
26.03.Serina Therapeutics GAAP EPS of -$1.91, revenue of $0.13M11
25.03.Serina Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
25.03.Serina Therapeutics, Inc.: Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights517- FDA Grants IND Clearance for SER-252- SER-252 Phase 1b Trial Initiated- Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics...
► Artikel lesen
25.03.Serina Therapeutics, Inc. - 10-K, Annual Report2
23.03.Serina Therapeutics, Inc. - 8-K, Current Report3
19.03.Serina Therapeutics Shares Surge 70% On Private Placement7
19.03.Serina Therapeutics (SER) Stock Surges Over 39% After Hours- Here's Why10
18.03.Serina Therapeutics secures up to $30M in private placement9
18.03.Serina Therapeutics, Inc.: Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease2
24.02.Serina Therapeutics, Inc.: Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease261- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 - - Advancement reflects continued execution...
► Artikel lesen
19.02.First patient enrolled in Serina's Parkinson's disease trial4
19.02.Serina Therapeutics, Inc.: Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease302- First patient successfully enrolled in global registrational study in Australia - Operational presence in Australia positions Serina to advance enrollment in Cohort 1- Company remains on track for...
► Artikel lesen
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1